M. P. Gamcsik, M. Kasibhatla, Stephanie D. Teeter, M. Colvin
2012.8.20BIOMARKERS
tlooto Summary
Clinical studies in which glutathione was measured in tumor tissue from patients with brain, breast, gastrointestinal, gynecological, head and neck and lung cancer are summarized and approaches that may improve the clinical value of glutATHione as a biomarker are recommended.
Abstract
This review summarizes clinical studies in which glutathione was measured in tumor tissue from patients with brain, breast, gastrointestinal, gynecological, head and neck and lung cancer. Glutathione tends to be elevated in breast, ovarian, head and neck, and lung cancer and lower in brain and liver tumors compared to disease-free tissue. Cervical, colorectal, gastric, and esophageal cancers show both higher and lower levels of tumor glutathione. Some studies show an inverse relationship between patient survival and tumor glutathione. Based on this survey, we recommend approaches that may improve the clinical value of glutathione as a biomarker.
Citation format
GAMCSIK, M. P., et al. Glutathione levels in human tumors. BIOMARKERS, 2012, 17: 671–691.